EUDA Health Announces Second Amendment to Streeterville Warrant Agreement

Rhea-AI Summary

EUDA Health (NASDAQ: EUDA) announced a second amendment to its Streeterville warrant agreement dated January 13, 2026. The amendment reduces the warrant exercise price from US$4.00 to US$2.00 and lowers the forced-exercise minimum closing price from US$6.00 to US$3.00. All other warrant terms remain unchanged. Management described the change as a technical adjustment to align terms with current market conditions while preserving capital-structure flexibility and maintaining the company’s strategic focus on preventive health, longevity, and personalised healthcare.

Positive

• Warrant exercise price reduced from US$4.00 to US$2.00
• Forced-exercise threshold lowered from US$6.00 to US$3.00
• Amendment dated January 13, 2026 preserves other warrant terms

Negative

• Potential for increased share dilution if warrants are exercised at US$2.00

News Market Reaction

-4.19%

2 alerts

-4.19% News Effect

-4.2% Trough Tracked

-$3M Valuation Impact

$76M Market Cap

0.0x Rel. Volume

On the day this news was published, EUDA declined 4.19%, reflecting a moderate negative market reaction. Argus tracked a trough of -4.2% from its starting point during tracking. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $3M from the company's valuation, bringing the market cap to $76M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Warrant exercise price (prior): US$4.00 per share Warrant exercise price (new): US$2.00 per share Forced exercise trigger (prior): US$6.00 +1 more

4 metrics

Warrant exercise price (prior) US$4.00 per share Original Streeterville warrant terms before second amendment

Warrant exercise price (new) US$2.00 per share Reduced exercise price under Second Warrant Amendment dated Jan 13, 2026

Forced exercise trigger (prior) US$6.00 Previous minimum closing price to trigger forced exercise

Forced exercise trigger (new) US$3.00 Reduced minimum closing price to trigger forced exercise

Market Reality Check

Price: $1.59 Vol: Volume 144,353 vs 20-day ...

low vol

$1.59 Last Close

Volume Volume 144,353 vs 20-day average 1,375,169 (relative volume 0.1) indicates muted trading interest. low

Technical Price at $1.91, trading below 200-day MA of $2.90 and well under 52-week high of $4.50.

Peers on Argus

EUDA fell 9.05% while key peers were mixed, with at least one scanner peer (DUO)...

1 Up

EUDA fell 9.05% while key peers were mixed, with at least one scanner peer (DUO) moving up. This suggests the move was stock-specific to the warrant amendment rather than a sector rotation.

Historical Context

5 past events · Latest: Jan 13 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 13	Convertible loan deal	Positive	-13.9%	Convertible loan to fund Shenzhen cGMP facility upgrade and platform expansion.
Jan 07	Warrant amendment	Neutral	+5.7%	First Streeterville warrant amendment lowering exercise and forced exercise thresholds.
Dec 30	China stem cell platform	Positive	+0.0%	Launch of nationwide stem cell extraction, storage and delivery platform in China.
Dec 29	Product launch update	Positive	-4.5%	Announcement of EUDA Helixé 2.0 longevity supplement and formulation upgrades.
Dec 23	Stem cell clinic launch	Positive	+41.2%	Launch of comprehensive stem cell therapy platform and first Shenzhen longevity clinic.

Pattern Detected

EUDA’s stock has shown volatile and sometimes negative reactions around growth and financing-related announcements, with both sharp rallies and pronounced selloffs following news.

Recent Company History

Over the last few weeks, EUDA announced multiple strategic steps, including a Shenzhen stem cell clinic and platform launch on Dec 23, 2025, a nationwide China stem cell platform on Dec 30, 2025, and the planned launch of EUDA Helixé 2.0 in Jan 2026. Financing activity included an amendment to the Streeterville warrant on Jan 7, 2026 and a convertible loan agreement on Jan 13, 2026. Price reactions ranged from a 41.18% surge to a 13.93% drop, underscoring sensitivity to capital structure and growth news.

Market Pulse Summary

This announcement further lowers the Streeterville warrant exercise price to US$2.00 and the forced ...

Analysis

This announcement further lowers the Streeterville warrant exercise price to US$2.00 and the forced exercise trigger to US$3.00, tightening the link between EUDA’s equity value and this financing instrument. In context of recent stem cell platform launches and a convertible loan for facility upgrades, investors may watch how capital structure changes interact with growth plans, particularly the balance between flexibility and potential dilution as the China longevity strategy scales.

Key Terms

warrant agreement, exercise price, forced exercise, capital structure

4 terms

warrant agreement financial

"entered into a second amendment to its previously disclosed warrant agreement with Streeterville"

A warrant agreement is the legal document that lays out the rules for stock warrants — special certificates that let their holder buy company shares at a set price within a certain time. It explains how and when warrants can be exercised, transferred, changed, or canceled, and what happens to them if the company raises money or is sold; investors care because these terms affect potential future ownership, dilution of shares, and the real value of the warrants.

exercise price financial

"agreed to further reduce the exercise price of the warrant from US$4.00 per share to US$2.00"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

forced exercise financial

"minimum closing price ... required to trigger a forced exercise under the warrant"

Forced exercise occurs when the issuer of options or warrants compels holders to convert those instruments into shares (or pay the strike) before the planned expiry, based on contract terms that allow such early conversion. It matters to investors because it can increase the number of outstanding shares and dilute existing ownership, oblige option holders to pay cash or accept shares sooner than expected, and thereby affect a company’s share price and capital structure — like being told to redeem a coupon early, changing everyone’s stake and the company’s cash position.

capital structure financial

"align the warrant terms with current market conditions and to preserve flexibility in our capital structure"

Capital structure is the way a company finances its operations and growth by using different sources of money, such as borrowed funds (loans or bonds) and owner’s equity (investments from owners or shareholders). It’s like a recipe for baking a cake, where the balance of ingredients affects the final product's strength and taste; similarly, the mix of debt and equity influences a company's stability and risk. For investors, understanding a company's capital structure helps gauge how risky it might be to invest or lend money.

AI-generated analysis. Not financial advice.

SINGAPORE, Jan. 15, 2026 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (NASDAQ: EUDA) (“EUDA” or the “Company”), a Singapore based non-invasive healthcare provider in Asia focused on Singapore, Malaysia and China, today announced that it has entered into a second amendment to its previously disclosed warrant agreement with Streeterville Capital, LLC.

Summary of Second Warrant Amendment Terms

Under the terms of the Second Warrant Amendment dated January 13, 2026, the Company and Streeterville Capital agreed to further reduce the exercise price of the warrant from US$4.00 per share to US$2.00 per share. In addition, the minimum closing price of the Company’s ordinary shares required to trigger a forced exercise under the warrant was reduced from US$6.00 to US$3.00. All other terms of the warrant remain unchanged.

Mr Alfred Lim, Chief Executive Officer of EUDA, commented:

“We view this second amendment as a technical adjustment to align the warrant terms with current market conditions and to preserve flexibility in our capital structure. It does not change our long-term strategy or operational priorities, and we remain focused on executing our business plan across preventive health, longevity solutions, and personalised healthcare.”

About EUDA Health Holdings Limited

EUDA Health Holdings Limited (NASDAQ: EUDA) is a Singapore-based leading non-invasive healthcare provider in Asia with a focus on Singapore, Malaysia and China. The Company aims to become a market leader in non-invasive and preventive healthcare, with a strategic focus on the fast-growing longevity sector. Our mission is to address the evolving healthcare needs of over 1.8 billion people across the region which is experiencing significant demographic shifts as more than 30% of the population ages rapidly. By offering innovative, accessible, and science-backed health solutions, EUDA is positioned to lead the transformation of regional healthcare from reactive medical treatment to proactive, longevity-focused care. EUDA also runs a Singapore-based property management business.

Forward-Looking Statements

This document may contain forward-looking statements regarding risks and uncertainties. These statements usually use forward-looking words, such as the words “estimates,” “projected,” “expects,” “envisions,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,” “propose” and variations of these words or similar expressions (or the negative versions of such words or expressions). These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside EUDA’s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. You should not overly rely on forward-looking statements that are only applicable to the date of publication of this document. The Company does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Christensen Advisory

Christian Arnell
Phone: + 852 9040 0621
Email: christian.arnell@christensencomms.com

FAQ

What did EUDA announce on January 15, 2026 about the Streeterville warrant?

EUDA said it entered a second amendment (dated Jan 13, 2026) reducing the warrant exercise price to US$2.00 and the forced-exercise trigger to US$3.00.

How does the January 13, 2026 amendment change the EUDA warrant exercise price?

The amendment lowers the exercise price from US$4.00 to US$2.00.

What is the new forced-exercise minimum closing price for EUDA warrants (NASDAQ: EUDA)?

The minimum closing price required to trigger forced exercise was reduced to US$3.00.

Do any other terms of the Streeterville warrant change under the January 13, 2026 amendment?

No; the company said all other terms remain unchanged.

How might the EUDA warrant amendment affect shareholders and the capital structure?

Lower exercise and trigger prices increase the possibility of warrant conversion, which could lead to additional shares outstanding if exercised.